Liat B. Hogen

Erratum to 'Factors influencing surgeons' decision for diverting ileostomy and associated complications in ovarian cancer cytoreductive surgery' [International Journal of Gynecological Cancer Volume 35 Issue 4 (2025) 101640].

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: June 12, 2025

Description of first recurrence in advanced stage high grade serous ovarian cancer receiving intraperitoneal versus intravenous systemic treatment.

Journal: Gynecologic oncology

Published: June 04, 2025

Tumor and germline testing with next generation sequencing in epithelial ovarian cancer: a prospective paired comparison using an 18-gene panel.

Journal: Molecular oncology

Published: April 29, 2025

Treatment Strategy and Residual Disease as Determinants of Survival in Stage IVB High-Grade Serous Ovarian Cancer: A Retrospective Cohort Study.

Journal: Journal of surgical oncology

Published: April 06, 2025

Association of frailty with healthcare utilization and days alive at home in patients with gynecologic cancers: a population-based study.

Journal: American journal of obstetrics and gynecology

Published: March 26, 2025

Association of frailty with perioperative and survival outcomes in patients with gynecologic cancers: A population-based study.

Journal: Gynecologic oncology

Published: February 22, 2025

Frailty Assessment for Risk prediction in Gynecologic Oncology patients undergoing surgery and chemotherapy (FARGO) study protocol: Rationale and design of a multi-centre prospective cohort study.

Journal: PloS one

Published: January 06, 2025

Factors influencing surgeons' decision for diverting ileostomy and associated complications in ovarian cancer cytoreductive surgery.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: October 19, 2024

Anastomotic diversion rates following integration of indocyanine green fluorescence angiography in cytoreductive surgery for ovarian cancer.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: September 05, 2024

Primary cytoreductive surgery compared with neoadjuvant chemotherapy in patients with BRCA mutated advanced high grade serous ovarian cancer: 10 year survival analysis.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: March 28, 2024

Erratum to 'Factors influencing surgeons' decision for diverting ileostomy and associated complications in ovarian cancer cytoreductive surgery' [International Journal of Gynecological Cancer Volume 35 Issue 4 (2025) 101640].

Erratum to 'Factors influencing surgeons' decision for diverting ileostomy and associated complications in ovarian cancer cytoreductive surgery' [International Journal of Gynecological Cancer Volume 35 Issue 4 (2025) 101640].

Description of first recurrence in advanced stage high grade serous ovarian cancer receiving intraperitoneal versus intravenous systemic treatment.

Description of first recurrence in advanced stage high grade serous ovarian cancer receiving intraperitoneal versus intravenous systemic treatment.

Tumor and germline testing with next generation sequencing in epithelial ovarian cancer: a prospective paired comparison using an 18-gene panel.

Tumor and germline testing with next generation sequencing in epithelial ovarian cancer: a prospective paired comparison using an 18-gene panel.

Treatment Strategy and Residual Disease as Determinants of Survival in Stage IVB High-Grade Serous Ovarian Cancer: A Retrospective Cohort Study.

Treatment Strategy and Residual Disease as Determinants of Survival in Stage IVB High-Grade Serous Ovarian Cancer: A Retrospective Cohort Study.

Association of frailty with healthcare utilization and days alive at home in patients with gynecologic cancers: a population-based study.

Association of frailty with healthcare utilization and days alive at home in patients with gynecologic cancers: a population-based study.

Association of frailty with perioperative and survival outcomes in patients with gynecologic cancers: A population-based study.

Association of frailty with perioperative and survival outcomes in patients with gynecologic cancers: A population-based study.

Frailty Assessment for Risk prediction in Gynecologic Oncology patients undergoing surgery and chemotherapy (FARGO) study protocol: Rationale and design of a multi-centre prospective cohort study.

Frailty Assessment for Risk prediction in Gynecologic Oncology patients undergoing surgery and chemotherapy (FARGO) study protocol: Rationale and design of a multi-centre prospective cohort study.

Factors influencing surgeons' decision for diverting ileostomy and associated complications in ovarian cancer cytoreductive surgery.

Factors influencing surgeons' decision for diverting ileostomy and associated complications in ovarian cancer cytoreductive surgery.

Anastomotic diversion rates following integration of indocyanine green fluorescence angiography in cytoreductive surgery for ovarian cancer.

Anastomotic diversion rates following integration of indocyanine green fluorescence angiography in cytoreductive surgery for ovarian cancer.

Primary cytoreductive surgery compared with neoadjuvant chemotherapy in patients with BRCA mutated advanced high grade serous ovarian cancer: 10 year survival analysis.

Primary cytoreductive surgery compared with neoadjuvant chemotherapy in patients with BRCA mutated advanced high grade serous ovarian cancer: 10 year survival analysis.

Sustainability of an enhanced recovery pathway after minimally invasive gynecologic oncology surgery.

Sustainability of an enhanced recovery pathway after minimally invasive gynecologic oncology surgery.

Validation of the Integrated Prediction Model algorithm for outcome of cytoreduction in advanced ovarian cancer.

Validation of the Integrated Prediction Model algorithm for outcome of cytoreduction in advanced ovarian cancer.